-
1 Comment
StemRIM is currently in a long term downtrend where the price is trading 1.2% below its 200 day moving average.
From a valuation standpoint, the stock is 70.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 20.7.
StemRIM's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 108.9% to $-515M since the same quarter in the previous year.
Based on the above factors, StemRIM gets an overall score of 1/5.
| Exchange | TSE |
|---|---|
| CurrencyCode | JPY |
| ISIN | JP3399690001 |
| Sector | Healthcare |
| Industry | Biotechnology |
| PE Ratio | None |
|---|---|
| Target Price | 700 |
| Beta | 0.98 |
| Market Cap | 18B |
| Dividend Yield | None |
StemRIM, a biotechnology company, develops regeneration medicines for the treatment of intractable diseases. The company develops PJ1, a regeneration induction medicine HMGB1 peptides, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, cerebral infarction, osteoarthritis, and chronic liver disease, as well as cardiomyopathy. Its pre-clinical stage products include PJ2 and PJ3 to treat multiple tissue damage disease; PJ4, an autologous cell sampling device for medical treatment; and PJ5, a stem cell gene therapy. StemRIM was incorporated in 2006 and is based in Ibaraki, Japan.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 4599.TSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
